Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

by arresting mitosis and cell proliferation without impacting unrelated, normal cellular functions, thereby avoiding many of the toxicities commonly experienced by patients treated with existing anti-mitotic drugs.

About Cytokinetics

Cytokinetics is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that may address areas of significant unmet clinical needs. Cytokinetics development efforts are directed to advancing multiple drug candidates through clinical trials to demonstrate proof-of-concept in humans, specifically in the areas of heart failure and cancer. Cytokinetics' cardiovascular disease program is focused to cardiac myosin, a motor protein essential to cardiac muscle contraction. Cytokinetics lead compound from this program, CK-1827452, a novel small molecule cardiac myosin activator, recently entered Phase II clinical trials for the treatment of heart failure in 2007. Under a strategic alliance established in 2006, Cytokinetics and Amgen Inc. plan to conduct research with activators of cardiac myosin in order to identify potential treatments for patients with heart failure. Amgen has obtained an option for the joint development and commercialization of CK-1827452 exercisable during a defined period, the ending of which is dependent on Cytokinetics conduct of further clinical trials of CK-1827452. Cytokinetics cancer program is focused on mitotic kinesins, a family of motor proteins essential to cell division. Cytokinetics is developing two novel drug candidates that have arisen from this program, ispinesib and SB-743921, each a novel inhibitor of kinesin spindle protein (KSP), a mitotic kinesin. Ispinesib has been the subject of a broad clinical trials program comprised of nine Phase II clinical trials as well as six Phase I or Ib clinical trials. Cytokinetics plans to conduct additional clinical trials with ispinesib and is conducting a Phase I/II trial of SB-74392
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:5/22/2015)... 22, 2015   InspireMD, Inc. (NYSE MKT: NSPR) ... systems ("EPS"), today announced that its CGuard TM Embolic ... investigator Prof. Piotr Musialek , at the EuroPCR ... France . PARADIGM, an investigator-initiated P ... A roti D revascularization I n symptomatic and ...
(Date:5/22/2015)... 22, 2015 Today, Rhodes Pharmaceuticals L.P. announced ... stimulant indicated for the treatment of Attention-Deficit/Hyperactivity Disorder ... 2015. The announcement comes just ... the U.S. Food and Drug Administration (FDA). ... of methylphenidate capsule with an onset of effect ...
(Date:5/22/2015)... LONDON , May 22, 2015 ... early phase clinical research unit with a worldwide ... respected for its frequent publications in peer reviewed ... and European stakeholders and regulators in discussions about ... results.      (Logo: http://photos.prnewswire.com/prnh/20150522/745125) , ...
Breaking Medicine Technology:InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6
... WASHINGTON, Aug. 10, 2011 In a just-released National ... Treatment http://www.nmqf.org/IB3SpecialtyTiersFinal.pdf ), Gary Puckrein ... has become popular among insurers (public and private) as ... requiring beneficiaries to pay more for certain high-cost prescription ...
... and ST. AUGUSTINE, Fla., Aug. 10, 2011 ... hospitals, has selected the Sunrise Enterprise ™ suite ... (NASDAQ: MDRX).  In addition to implementing Sunrise within the ... Electronic Health Record (EHR) and practice management solution ...
Cached Medicine Technology:Prescription-Drug Plans' Use of Specialty Tiers Promotes Inequalities 2Flagler Hospital Selects the Sunrise Enterprise Acute Care Solution From Allscripts 2Flagler Hospital Selects the Sunrise Enterprise Acute Care Solution From Allscripts 3Flagler Hospital Selects the Sunrise Enterprise Acute Care Solution From Allscripts 4Flagler Hospital Selects the Sunrise Enterprise Acute Care Solution From Allscripts 5Flagler Hospital Selects the Sunrise Enterprise Acute Care Solution From Allscripts 6
(Date:5/25/2015)... A recent report for Mass Live ... died as a direct result of an opiate overdose in ... rise in overdose deaths attributed to prescription opiate medications, and ... care about geography. This issue doesn’t care about race. This ... class.” As the state of Mass. reels from the effects ...
(Date:5/25/2015)... After the sensational buzz surrounding their ... wellness company Trivedi Master Wellness™ agrees to ... series titled, “Consciousness is Power.” Presently, the Live-Streaming event ... at the routinely allotted time from 10:00pm PST/1:00pm EST ... made available to the public and accessible on the ...
(Date:5/24/2015)... New York, NY (PRWEB) May 24, 2015 ... begins on Sunday, May 24th in San Diego at Petco ... tour throughout North America. On May 20th, they had ... Theatre. At their preview show in Los Angeles, this ... its entirety; they also played fan favorites such as "Jumping ...
(Date:5/24/2015)... 24, 2015 EnviroLeather™ by LDI, ... Plus” – a classic, rugged leather grain with ... difficult stains, including ink, to be easily removed. ... suitable for corporate, healthcare, hospitality and education environments. ... EnviroLeather’s goal of developing products that are more ...
(Date:5/24/2015)... 24, 2015 ... - The students were selected ... the fourth annual A Day of ... Geneva National in Lake Geneva. , ... High School,         Jonathan Alfonso,         Bridget Keefe, ...
Breaking Medicine News(10 mins):Health News:Opioid Deaths Increase by 33 Percent Since 2012 in Mass. 2Health News:Hundreds of People Are Thrilled to Hear that Trivedi Master Wellness™ Promises to Hold Another Workshop in June 2015 2Health News:Hundreds of People Are Thrilled to Hear that Trivedi Master Wellness™ Promises to Hold Another Workshop in June 2015 3Health News:The Rolling Stones Tickets in San Diego, Orlando, Minneapolis, Dallas, Pittsburgh, Indianapolis, Atlanta, Detroit, Milwaukee, Kansas City, Columbus, Nashville & Raleigh 2Health News:EnviroLeather By LDI Launches "InkGard Plus" - Stain Resistant Faux Leather 2Health News:Mercy Foundation Honors 16 Students for Making a Difference - Mercy Health System Javon Bea 2
... initiated by World Health,Organization's (WHO) authority to ... unofficial,sources, soon after any outbreak of infectious,diseases ... a crucial decision it was decided that ... on-the-spot,investigations to determine the severity of an,outbreak ...
... on its border with hard-hit China. ,The first confirmed case ... the Amur river, which forms the frontier with China, came ... his country could contain the disease.,Hu told students in Moscow, ... introduced strict measures to stop the spread of the deadly ...
... may benefit non-anemic women between ages 18 and 55 with ... with low ferritin, a protein that stores iron and is ... of Lausanne in Switzerland gave 136 women either 80 milligrams ... The study shows the level of fatigue after one month ...
... The global health community has taken a key ... of infectious diseases and other threats to international ... underlines the World Health Organization’s (WHO) authority to ... unofficial sources, and, when necessary to determine the ...
... the illness have been told to quarantine themselves at ... chief medical officer of health. Precautions taken at ... control dozens of possible new cases. Health officials ... city back on its list of SARS - affected ...
... may have a potential role in treating Alzheimer's. Lithium ... of both the proteins found in Alzheimer's patients. Identification ... other drugs that disrupt the production of both proteins., ... not disrupt the processing of another protein called notch, ...
Cached Medicine News:Health News:WHO Says Toronto Going Back on SARS-Affected List 2Health News:Lithium May help in Alzheimer's Disease 2
The playful pattern of this lens features sky-blue forms fanning out from the center of your eye....
Each jet black lens features a mesmerizing thin white line that spirals toward the center of the pupil....
The opaque outer circle will white-out even the darkest iris, making your pupil the only spot of black in a sea of white....
Yellow flames radiate out from the center of eye, held in check by the fire-engine red perimeter....
Medicine Products: